Skip to content

Optimization effect of intravenous pre injection of Namefene on labor analgesia

Optimization effect of intravenous pre injection of Namefene on labor analgesia - Optimization effect of intravenous pre injection of Namefene on labor analgesia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097478
Enrollment
Unknown
Registered
2025-02-19
Start date
2023-06-30
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

labor analgesia

Interventions

Group S:Saline 5 ml was given intravenously and epidural anesthesia was administered after 10 minutes.
Group D1:0.1 µg/kg nalmefene 5 ml i.v. was given and epidural anesthesia was administered after 10 minutes.
Group D2:0.2 µg/kg nalmefene 5 ml i.v. was given and epidural anesthesia was administered after 10 minutes.

Sponsors

Yuhuangding Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
24 Years to 36 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (1) complete medical history; (2) age 24-36 years old; (3) full-term, singleton, term primigravida; (4) ASA grading of grade I-II; (5) normal pelvic measurements, eligible for vaginal trial of labor; and (6) informed consent of the patient and her family members and signing of an informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria: (1) contraindications related to labor and delivery; (2) contraindications to anesthesia; (3) severe pregnancy complications such as hypertension, heart disease, preeclampsia, and hepatic and renal insufficiency, etc.; (4) mental disorders; (5) any history of itch-related diseases or pruritus before labor analgesia; (6) nausea and vomiting before labor analgesia; (7) opioid dependence or allergy to nalmefene; (8) nausea and vomiting before labor analgesia. or nalmefene allergy.

Design outcomes

Primary

MeasureTime frame
Pruritic;

Secondary

MeasureTime frame
Nausea and vomiting;Pain scores;Total Sufentanil dosage;Vital signs;Mother and child ending;Maternal satisfaction;

Countries

China

Contacts

Public ContactJiang Aihua

Yantai Yuhuangding Hospital

jahzy@126.com+86 138 6388 0266

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026